Polymer-drug conjugates: origins, progress to date and future directions - Test2 - elhamkhani - TriplyDB

Polymer-drug conjugates: origins, progress to date and future directions

Polymer-drug conjugates: origins, progress to date and future directions

http://www.wikidata.org/entity/Q27002505

about

Nanoparticle-mediated drug delivery for treating melanoma Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges Drug Carriers: Not an Innocent Delivery Man Clinical Translation of Nanomedicine.The Theranostic Path to Personalized Nanomedicine Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs.Immunogenicity of coiled-coil based drug-free macromolecular therapeutics.Macromolecular therapeutics Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.Specific tumor labeling enhanced by polyethylene glycol linkage of near infrared dyes conjugated to a chimeric anti-carcinoembryonic antigen antibody in a nude mouse model of human pancreatic cancer Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy.Non-invasive, real-time reporting drug release in vitro and in vivo Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting POLYMERIC BIOMATERIALS AND NANOMEDICINES.Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic.Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.Diverse Applications of Nanomedicine.Advances in Polymer and Polymeric Nanostructures for Protein Conjugation.Hyaluronic acid conjugates as vectors for the active targeting of drugs, genes and nanocomposites in cancer treatment.Polyphosphazenes: Multifunctional, Biodegradable Vehicles for Drug and Gene Delivery.Polymer-drug conjugates: recent progress on administration routes.Selective uptake of cylindrical poly(2-oxazoline) brush-antiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-cell activation.Role of polymer-drug conjugates in organ-specific delivery systems.Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.Smart branched polymer drug conjugates as nano-sized drug delivery systems.Magnetic Resonance-Guided Drug Delivery.Current status and future perspectives of fluorescence-guided surgery for cancer.Recent advances in nanomedicines for the treatment of rheumatoid arthritis.Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease.

P2860

Q26798379-F39303B4-96C9-4C1F-9A6A-A181473D0E6A Q26995399-94401B2E-95ED-400B-9744-AAC9FB539CA1 Q28082414-FBEB91E9-EB47-4E9A-9CC0-4330F986EDCA Q30355939-C89DCE7C-DB4C-4D1F-853C-E80118604886 Q30437998-24FF63E9-8236-49C0-95D4-5CD9CE1A49F4 Q30451024-454D9297-B61B-41EA-B210-5008D175AD65 Q33602669-92C247EA-661D-4151-94E1-1EFA7E39D239 Q34079574-2C260055-36C0-4EE9-94B1-7000570C2843 Q34082844-8586D4C5-586C-4E6D-9177-6FBEA82F80C8 Q34163904-F2E517B6-BE85-4A0B-A123-3C27B9D8995E Q34292505-A318747D-BA1A-40DB-BC91-C8A44C9E89DE Q35800904-2B498343-15AD-4228-8B14-350AC54F7C10 Q35861726-07833C07-F305-47CD-9483-E6A68E3E9D45 Q36244719-1F4CB576-3B02-4ACD-AC70-AED60BA404F1 Q36327549-89D63AC6-574A-4566-95A5-4E0137C011C8 Q36376467-0495EF26-39CA-4ACE-B370-7153C238A931 Q36623111-02D65751-1577-424F-BE24-CED73971BF0A Q36722841-E33B8E4A-5F5A-49BE-95C0-97FF58A5D30D Q36821353-A5F92CFE-68F4-4259-A39B-5E3EF5A608DD Q36940281-4DC1C05B-F171-493C-BDD5-7209B1F9E4FB Q36942446-F0B4FFDC-9240-48FE-8982-93EA4DC49D8E Q37013316-9F21D572-997C-4F1E-96C1-D680449AF45C Q37206486-515ED350-5233-411E-9D73-EFB639DA7CD8 Q37260923-082AE0F2-40A4-4D62-BCFD-1667BE0F21BE Q37381330-7B58E709-BF31-4D04-9820-789F22D2B88C Q37393951-0941E0DF-28A9-470A-99F9-7A391250049D Q37635484-DFFF3992-53DD-4350-A58E-DB353CDF8641 Q37728142-ED783753-BFAA-4455-9AD0-6174911D284C Q38140845-744A4261-80EE-4BA7-A837-C301EA1FB0A0 Q38197045-19B5C2C2-C475-4884-AACD-47D59D19AC1D Q38204376-85CE4656-C537-4F6C-9DAB-346DFC2D1A8A Q38206549-6977CD27-B6E5-4C47-80F4-CEF986682B27 Q38305108-BE15A5DF-C67A-4258-9AFE-9D1FE3DB19B1 Q38365556-DA2DD997-42EE-4F51-B13F-54FB8312C099 Q38494691-23C79FB3-BCB0-4801-961D-C5D986D0AE6F Q38565174-90449B97-B56D-4E5C-9CC2-253971610804 Q38616007-7CB33001-F707-4D85-9E04-D0DDB040A531 Q38633227-26264390-5401-42A9-860A-81E23D409226 Q38669113-A8908C22-C6BD-4D8C-9EE6-1DE219EDD529 Q38680244-8F9180E3-B80C-4497-AC6D-21E2C17D15DD

P2860

Polymer-drug conjugates: origins, progress to date and future directions

http://www.wikidata.org/entity/Q27002505

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Polymer-drug conjugates: origins, progress to date and future directions

@ast

Polymer-drug conjugates: origins, progress to date and future directions

@en

Polymer-drug conjugates: origins, progress to date and future directions

@nl

type

label

Polymer-drug conjugates: origins, progress to date and future directions

@ast

Polymer-drug conjugates: origins, progress to date and future directions

@en

Polymer-drug conjugates: origins, progress to date and future directions

@nl

prefLabel

Polymer-drug conjugates: origins, progress to date and future directions

@ast

Polymer-drug conjugates: origins, progress to date and future directions

@en

Polymer-drug conjugates: origins, progress to date and future directions

@nl

P1433

Q27002505-6E5933C5-72D9-47D6-B729-A21D082AD8F8

P1476

Q27002505-A7C2DAD2-6994-486E-A6DE-C67D3AF23C60

P2093

Q27002505-D0FF2793-62F5-4E5E-A4BB-388717CE78F1

P2860

Q27002505-0097B5F8-62FF-4BBF-8C3A-F2C8BDCB6090

Q27002505-038DACE3-9345-4BDC-9F9F-604C5C41A40A

Q27002505-0540D1EF-68F5-4C68-9637-E968AE342285

Q27002505-0850AD67-B849-4480-B25D-6E186805F571

Q27002505-0A077156-B02B-4525-8DDF-AEF8A925FD80

Q27002505-0A9B5B79-290A-4912-ACCE-F2A73D309696

Q27002505-0B171591-F7B8-4B87-A1D6-C0C6969DD5FA

Q27002505-0CE0F3A1-C84F-414E-B884-ABCF0F036297

Q27002505-0E036542-4AC8-4E29-9F71-3DF3CEC36853

Q27002505-0F7A7439-92DD-4DAB-B171-37BDD6940BF3

P304

Q27002505-BA76BE57-5827-484B-9C4B-87D6B7757B1A

P31

Q27002505-38AF7B51-2205-4CD8-A867-B643FAF2FDFD

P3181

Q27002505-F0D51CE2-80DF-41ED-BEFC-C9E4059EABEE

P356

Q27002505-A1528DCC-91FD-4DFA-8C44-22C1B6124C56

P407

Q27002505-6E03FD14-9B2A-4D9D-B3B3-E04A41CDD4B5

P433

Q27002505-D1821329-5EC5-4DCB-B5CA-FA8810A76953

P478

Q27002505-2FDFE9D6-DC86-4BF2-8213-A2B4C4E245D5

P577

Q27002505-3E65195A-F257-44F8-A61E-930232B11C22

P5875

Q27002505-AD75C70D-A9E4-4A16-827A-A2A7BFACF887

P698

Q27002505-470F14DF-BF28-4DF8-8B1D-6111B70BA5BE

P932

Q27002505-95954851-A4B9-4E66-861C-FC57787B2847

P3181

P356

J.ADDR.2012.10.014

P1433

Advanced Drug Delivery Reviews

P1476

Polymer-drug conjugates: origins, progress to date and future directions

@en

P2093

Jindřich Kopeček

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular imaging in drug development

Imaging in the era of molecular oncology.

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

Development of macromolecular prodrug for rheumatoid arthritis

Pegaspargase: a review of clinical studies

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

P304

49-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2673473

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.ADDR.2012.10.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232811916

http://www.w3.org/2001/XMLSchema#string

P698

23123294

http://www.w3.org/2001/XMLSchema#string

P932

3565043

http://www.w3.org/2001/XMLSchema#string